EVE (NYSE:EVEX – Free Report) had its target price reduced by Canaccord Genuity Group from $9.00 to $8.50 in a research note issued to investors on Tuesday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.
Separately, Cantor Fitzgerald reaffirmed a neutral rating and set a $7.00 price objective on shares of EVE in a research note on Monday.
View Our Latest Analysis on EVE
EVE Stock Down 0.9 %
EVE (NYSE:EVEX – Get Free Report) last posted its earnings results on Tuesday, May 7th. The company reported ($0.09) EPS for the quarter. On average, sell-side analysts expect that EVE will post -0.53 EPS for the current fiscal year.
Institutional Investors Weigh In On EVE
An institutional investor recently raised its position in EVE stock. Strs Ohio grew its holdings in shares of Eve Holding, Inc. (NYSE:EVEX – Free Report) by 3,883.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 47,800 shares of the company’s stock after purchasing an additional 46,600 shares during the quarter. Strs Ohio’s holdings in EVE were worth $349,000 at the end of the most recent quarter. 1.27% of the stock is owned by institutional investors and hedge funds.
EVE Company Profile
Eve Holding, Inc, together with its subsidiaries, develops urban air mobility solutions. It is involved in the design and production of electrical vertical take-off and landing vehicles (eVTOLs); provision of eVTOL service and support capabilities, including material services, maintenance, technical support, training, ground handling, and data services; and development of urban air traffic management systems.
Read More
- Five stocks we like better than EVE
- What is Forex and How Does it Work?
- RXO Shares Surge Following New Acquisition Deal
- How to Invest in Biotech Stocks
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for EVE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EVE and related companies with MarketBeat.com's FREE daily email newsletter.